CClinicalTrials.gg
CompletedNCT05457413Updated Apr 19, 2023

Impact of Bariatric Surgery on Women Fertility

An observational study in Fertility Issues, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Ain Shams University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Obesity is a multifactorial risk factor for subfertility, in relation to chronic hormonal change induced by adipose tissue. This prospective cohort study aims to evaluate the impact of bariatric surgery induced weight loss on women fertility.

Read the detailed description

Females undergoing sleeve gastrectomy will be assessed for improvement of fertility indicators

02

Conditions studied

  • Fertility Issues

Browse trials for

03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's enrollment of 75 is below the median of 200 across 714 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Obese females undergoing sleeve gastrectomy

Inclusion criteria

  • Age from 20-40 years.
  • BMI >35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Women with medical endocrinal disorders as DM, thyroid, hyperprolactinaemia, etc.
  • Women using any hormonal treatment or fertility drugs like oral contraceptive pills and/or metformin.
  • Women have any surgical complication intra-operatively or post operatively.
  • Women refused to participate in the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (actual)
Patient registry
No

Groups and cohorts

  • Sleeve gastrectomy

    Sleeve gastrectomy for weight loss

    Procedure: Sleeve gastrectomy

Interventions

  • ProcedureSleeve gastrectomy

    Bariatric surgery

06

What researchers measure

Primary outcomes

  1. Change in Antimullerian hormone level

    Change in antimullerian hormone level

    Time frame: 3 months

Secondary outcomes

  1. Change in serum FSH level

    Time frame: 3 months

  2. Change in serum LH level

    Time frame: 3 months

07

Study locations

1 site
  • Ain Shams University Maternity Hospital
    Cairo, Cairo/القاهرة 71350, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — Anonymous participants data will be available with principal investigator and director for any inquiries

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05457413
Lead sponsor
Ain Shams University
Responsible party
Sponsor
First posted
Jul 14, 2022
Start date
Jul 25, 2022
Primary completion
Dec 1, 2022
Completion
Mar 1, 2023
Last update
Apr 19, 2023

Study contacts

Maii Nawara
study director · Associate professor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion